Home | Welcome | Vision 10 | Mission Statement | HyperMED NeuroRecovery Foundation | Gallery | BLOG | Testimonial | Video | Newsletter

 Patient Application | HBO Direct | Beyond Therapy | Conditions | Google News | Clinical Research | Stem Cells | Mild HBO Chambers

Hyperbaric Oxygenation | Adult & Pediatric Lokomat (Robotic Assisted) Walking | Vibration Training | Median Nerve Stimulation | Oxy Sports

Disc Prolapse, Chronic Pain, Tarlov Cyst, Failed Back Surgery | Spinal Cord Injury | Stroke | Multiple Sclerosis | Brain Injury | Crush Injury

Autism, Speech and Development Delay | Cerebral Palsy, Birth (Hypoxia), Near Drowning | Neurologic Illness | Chronic Fatigue Syndrome
 Non-Healing Wounds | Cosmetic Mishap | Cancer Survival | Radiation Necrosis | Heart Disease | Infertility | HIV AIDS | Burns | Mental Health

CLINICAL RESEARCH - CEREBROLYSIN

HyperMED Clinical Research  provides links with all current publications on Hyperbaric Oxygenation, Lokomat (Robotic Gait Assisted Walking) and other break-through we believe relevant to the objective of NeuroRecovery.

Clinical Research:  Cerebrolysin

 

 

 

Cerebrolysin (Cere) is a compound with neurotrophic and neuroprotective activity that causes neuronal differentiation (sprouting of axons and dendrites) and maintains the functional integrity and recovery of the nerve cell. Pre-cerebrolysin pictured above left and after cerebrolysin right.

The true mechanism, by which this drug work in such a degenerative disease is still unknown, but probably the neuronal differentiation (sprouting of axons and dendrites) and the maintenance of the functional integrity of the nerve cell play a major role in the improvement encountered in this trial. [A. Mubaidin, A. Shurbaji, A. Hadid, N. Shishani: Cerebrolysin in Steel: Richardson-Olszewski Syndrome. The Internet Journal of Neurology. 2003. Volume 2 Number 1]

  • Cerebrolysin is a porcine (pig) brain derived peptide preparation; it is produced by enzymatic breakdown of purified brain proteins and consists of low molecular weight peptides and amino acids

  • Cerebrolysin facilitates neurotrophic activity which has been shown to improve cognitive performance and global function in numerous neurodegenerative disorders and mental illness. Significant improvement of cognitive function, clinical global impression and increased activities of daily living were observed

  • Cerebrolysin potentiates brain alpha activity, reduces slow EEG delta frequencies and improves memory performance in healthy elderly humans, suggesting that this compound activates cerebral mechanisms related to attention and memory processes.

  • Cerebrolysin is a safe product administered either intravenous and or intramuscular injection. The oral Cerebrolysin product is not as effective as the IV and IM application but useful in ongoing treatment recommendations

  • Cerebrolysin is a safe drug that improves the cognitive deficits and global function in patients with mild to moderate progressive neurodegenerative disease including Multiple Sclerosis, Parkinson’s Disease, Alzheimers Disease, Dementia, Acute and Chronic Stroke victims. Cerebrolysin also demonstrated significant improvement in victims of post-acute traumatic brain injury

  • Cerebrolysin demonstrated significant benefit in childhood autism (89%) and cerebral palsy (mild to complex anoxic encephalopathy)

  • Cerebrolysin protects against induced motor neuron damage and reduced imposed nerve death. Studies involving induced spinal cord and nerve root damage revealed significant motor recovery with Cerebrolysin

  • Cerebrolysin exerts a neuro-immunotrophic activity reducing the extent of chronic nerve cell inflammation and accelerated neuronal death under pathological conditions such as those observed in acute traumatic and chronic progressive neurodegenerative diseases (progressive arthritis)

  • Cerebrolysin demonstrates ‘anti-aging’ with benefits ‘improving cognition, memory function, brain metabolism with capacity

Neuroprotective and consequent neurorehabilitative clinical outcomes, in patients treated with the pleiotropic drug cerebrolysin.

Cerebrolysin administration, as neurorehabilitative outcomes, proved to hasten, statistically significant, especially the recovery of some critical, for standing and walking, parameters. Thus encouraged, we have now initiated a comprehensive national, 5 year retrospective, multi-centre--based on unitary data acquisition frame and mathematical apparatus--study, to evaluate the results of the treatment with Cerebrolysin in traumatic brain injuries (TBI).

Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer's disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin

At week 24, Cerebrolysin improved the global clinical function significantly with all three dosages and induced significant improvements in cognition, initiation of activities of daily living (ADL) and neuropsychiatric symptoms at 10-, 30- and 60-ml doses, respectively.

Spotlight on cerebrolysin in dementia

Cerebrolysin is a parenterally administered, porcine brain-derived peptide preparation that has pharmacodynamic properties similar to those of endogenous neurotrophic factors. In several randomized, double-blind trials of up to 28 weeks' duration in patients with Alzheimer's disease, Cerebrolysin was superior to placebo in improving global outcome measures and cognitive ability.

 

Clinical trials

The Safety and Efficacy of Cerebrolysin in Patients With Acute Ischemic Stroke

10-day course of therapy with daily intravenous administration of 30mL Cerebrolysin based on a comparison with Placebo in patients with acute ischemic stroke. ... randomized in this trial in 2 parallel groups one receiving Cerebrolysin the control group receiving Placebo.

Combined Treatment With Alteplase (rt-PA) and Cerebrolysin® in Acute Ischemic Hemispheric Stroke

ClinicalTrial... Combined Treatment With Alteplase (rt-PA) and Cerebrolysin® in Acute Ischemic Hemispheric Stroke (CERE-LYSE-1) ... Detailed Description: The current trial should evaluate a combined treatment using Cerebrolysin immediately after thrombolysis to guarantee that the neurotrophic components are able ... http://www.clinicaltrials.gov/ct2/show/NCT00840671?intr=%22Hematologic+Agents%22

Comparative Study to Test Safety and Efficacy of Neurotrophic and Cholinergic Treatment of Alzheimer's Disease

Study Results - ... when not all inclusion criteria were met or when exclusion criteria were applicable. Reporting Groups Description Cerebrolysin + Donepezil No text entered. ... Frequency Threshold for Reporting Other Adverse Events: 5% Other Adverse Events Cerebrolysin + Donepezil Cerebrolysin

Comparative Study to Test Safety and Efficacy of Neurotrophic and Cholinergic Treatment of Alzheimer's Disease

Tabular View - ... A Randomized Double-Blind Clinical Trial to Compare the Safety and Efficacy of Cerebrolysin and Aricept (Donepezil) and a Combination Therapy ... Brief Summary The study was performed to compare the safety and efficacy of Cerebrolysin (10 mililiters [ml]) Aricept

The Safety and Efficacy of Cerebrolysin in Patients With Acute Ischemic Stroke

ClinicalTrials.gov ... The Safety and Efficacy of Cerebrolysin in Patients With Acute Ischemic Stroke (CASTA) This study is currently recruiting participants.

 

Evidence Based

The effect of cerebrolysin on cognitive functions in childhood autism and in Asperger syndrome Zh Nevrol Psikhiatr Im S S Korsakova. 2003;103(6):15-8. Nineteen children with childhood autism and 8 with Asperger's syndrome aged 2-8 year, were treated with cerebrolysin (CL) in inpatient clinic. All the patients received 10 microinjections (intramuscularly and perinervously) of 0.1 ml CL daily during 5 days. Clinical study was combined with device estimation of cognitive functions and communicative skills. CL therapy resulted in improvement of cognitive functions (expressive and receptive speech, fine motoring, playing). Positive effects were revealed in all the patients with Asperger's syndrome and in 89% of the patients with childhood autism. Any negative effects were not found. With regard to cognitive functions development, therapeutic efficacy proved to be more pronounced in the patients with Asperger's syndrome as compared to childhood autistic group (p < 0.005)

Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. ... We explored the safety and preliminary outcome of Cerebrolysin treatment in patients with acute stroke. METHODS: Randomised ... Treatment emergent adverse events lab tests and vital signs were recorded to assess the safety of Cerebrolysin. RESULTS: 146 patients were enrolled in two groups: 78 Cerebrolysin and 68 placebo.

A double-blind, placebo-controlled, multicenter study of Cerebrolysin for Alzheimer's disease. ... Activities of Daily Living (IADL) Scale. RESULTS: After 4 weeks of treatment Cerebrolysin-treated patients demonstrated significant ... Cerebrolysin and placebo. Only one patient reported a febrile sensation which was transient and mild in severity. CONCLUSIONS: This study indicates that Cerebrolysin is a safe drug that improves the cognitive deficits and global function in patients with mild to moderate AD.

Sustained improvement of cognition and global function in patients with moderately severe Alzheimer's disease: a double-blind, ... placebo-controlled study with the neurotrophic agent Cerebrolysin. 265-75 BACKGROUND: In a recent study Cerebrolysin (Cere) a compound with neurotrophic activity has been shown to be effective in the treatment of mild to moderate Alzheimer's disease (AD).

Cochrane Reviews - Cerebrolysin for vascular dementia ... Title: Cerebrolysin for vascular dementia Stage:

Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. ... We explored the safety and preliminary outcome of Cerebrolysin treatment in patients with acute stroke. ... h of stroke onset to IV therapy with placebo or Cerebrolysin 50 mL/day for 21 days.

Meta-analysis: the efficacy of nootropic agent Cerebrolysin in the treatment of Alzheimer's disease. ... and communicated with EBEWE Pharmaceutical Ltd for randomized trials comparing Cerebrolysin with placebo in AD. Available data on clinical global ... (P 0.05) indicating that Cerebrolysin could significantly improve the clinical global impression in patients

A double-blind, placebo-controlled, multicenter study of Cerebrolysin for Alzheimer's disease. ... 1566-71 OBJECTIVE: To assess the efficacy and safety of Cerebrolysin over 4 weeks in patients with probable Alzheimer's disease (AD). ... double-blind placebo-controlled multicenter clinical trial. An unequal (Cerebrolysin:placebo = 2:1) randomization was used

Dose-dependent effects of Cerebrolysin on EEG and short-term memory of healthy volunteers during control and hyperventilation in ... The aim of this study was to examine the potential dose-dependent effects of Cerebrolysin on HV related EEG changes and short term memory during chronic ... enrolled and received either 100 ml placebo (NaCl) or Cerebrolysin (10 ml or 30 ml or 50 ml)

A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's ... 43-54 Cerebrolysin (Cere) is a compound with neurotrophic activity shown to be effective in Alzheimer's disease in earlier trials.

Efficacy of the peptidergic nootropic drug cerebrolysin in patients with senile dementia of the Alzheimer type (SDAT). ... Alzheimer type (SDAT). Experimental studies have shown Cerebrolysin to have a regulatory effect on energy metabolism a positive ... placebo or the drug once a day (30 ml Cerebrolysin in 100 ml physiological saline i.v. )

Cerebrolysin in Alzheimer's disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent. ... 1089-104 Cerebrolysin (Cere) is a compound with neurotrophic activity. It has been shown to be effective in the treatment

Pharmacological Treatment of Dementia: Structured Abstract ... Delay of disease progression: Cerebrolysin selegiline plus vitamin E and donepezil showed some significant effects in patients with mild-to-moderate and moderately severe Alzheimer's disease. ... and for AD and VaD. Trials with VaD patients showed effects for memantine nicergoline pentoxyfylline idebenone donepezil and cerebrolysin.

Cochrane Reviews - Cerebrolysin for acute ischemic stroke ... Title: Cerebrolysin for acute ischemic stroke Stage: Protocol

A 28-week, double-blind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer's disease. ... 253-63 Cerebrolysin (Cere) is a compound with neurotrophic activity which has been shown to be effective in the treatment of Alzheimer's disease

Sustained improvement of cognition and global function in patients with moderately severe Alzheimer's disease: a double-blind, ... 265-75 BACKGROUND: In a recent study Cerebrolysin (Cere) a compound with neurotrophic activity has been shown to be effective

Effects of N-PEP-12 on memory among older adults. ... 97-100 N-PEP-12 is a derivative of cerebrolysin a brain-derived neuropeptide compound that has been approved for the treatment of Alzheimer's disease ... N-PEP-12 is much less potent than cerebrolysin but it can be administered orally whereas the parent compound